Abstract:Cytokeratin 19 (CK19) is a complex intracytoplasmic cytoskeletal protein primarily localized in the ducts of the mammary gland and skin epithelial cells. In humans, the expression of CK19 gene within circulating tumor cells (CTCs) extracted from blood samples of breast cancer patients reflects tumor cell activity, offering valuable insights for predicting early metastatic relapse or monitoring treatment effectiveness. However, knowledge of serum tumor markers is limited in veterinary oncology. Recently, droplet digital PCR (ddPCR), has been employed to explore rare target genes due to its heightened sensitivity and accuracy as a novel molecular diagnostic tool. The objectives of this study were to investigate the expression of the CK19 mRNA in CTCs, non-neoplastic mammary tissues, and both benign and malignant canine mammary tumors (CMTs) through ddPCR analysis. In Study I, we optimized the discard volume for blood samples to reduce CK19 contamination from skin epithelial cells post-venipuncture. The results revealed that discarding the initial 3 mL of blood was adequate and effective in eliminating CK19 mRNA contamination. In Study II, after the removal of the initial 3 mL of blood, we investigated CK19 mRNA-positive CTCs in the peripheral blood of normal healthy dogs, including those with benign and malignant CMTs. Intriguingly, CK19 mRNA was undetectable in all blood samples. The expression of CK19 mRNA in mammary tissues was investigated in Study III. The copy number (CN) ratios of the CK19 gene in non-neoplastic mammary tissues (14.77 ± 14.65) were significantly higher (P < 0.05) than those in benign (4.23 ± 3.35) and malignant groups (6.56 ± 5.64). Notably, no difference was observed between the benign and malignant groups. In conclusion, CK19 mRNA appeared unlikely to be a suitable candidate as a biomarker in the peripheral blood of CMTs, while the CN ratio in mammary tissues could serve as a potential discriminator between non-neoplastic and CMT groups, complementing the gold standard of histopathological examination.

Research progress of good markers for canine mammary carcinoma

Current Research on Markers Related to Canine Mammary Cancer

The Analysis of E-Cadherin, N-Cadherin, Vimentin, HER-2, CEA, CA15-3 and SF Expression in the Diagnosis of Canine Mammary Tumors.

Diagnosis of Canine Tumours and the Value of Combined Detection of VEGF, P53, SF and NLRP3 for the Early Diagnosis of Canine Mammary Carcinoma

The Development of Molecular Typing in Canine Mammary Carcinomas

Novel promising serum biomarkers for canine mammary tumors

Potential Biomarkers of Malignancy in Canine Mammary Neoplasia

Clinico-Pathological, Immunohistochemical and In-Situ TUNEL ASSAY Observations of Canine Breast Tumors

PD-L1 mRNA and protein expression in canine mammary carcinomas: Correlation with histopathological grade and molecular markers

Canine Mammary Tumors as a Potential Model for Human Breast Cancer in Comparative Oncology

Microsatellite Instability and MMR Genes Abnormalities in Canine Mammary Gland Tumors

Expression and Significance of IL-6 and IL-8 in Canine Mammary Gland Tumors

Integrated Study of Canine Mammary Tumors Histopathology, Immunohistochemistry, and Cytogenetic Findings

Molecular Biological Aspects on Canine and Human Mammary Tumors

Quantification of VEGF-C Gene Expression in Canine Mammary Tumors by Real-Time Reverse Transcription Quantitative Polymerase Chain Reaction

Relation between expressions of PTEN and VEGF and clinicopathological features in canine mammary gland tumors

Detection of tumor necrosis factor-1 in canine mammary tumor tissues by fluorescent real-time polymerase chain reaction(PCR)

Advancing canine mammary tumor diagnostics: Unraveling the diagnostic potential of Cytokeratin 19 through droplet digital PCR analysis

Expression and significance of p63 and Calponin proteins in canine mammary tumors

Epidemiological Investigation of Canine Mammary Tumors in Mainland China Between 2017 and 2021

Expression and Prognosis of Hexokinase 2 in Canine Mammary Tumors